Knight Total Current Assets from 2010 to 2026
| GUD Stock | CAD 5.97 0.07 1.19% |
Total Current Assets | First Reported 2013-09-30 | Previous Quarter 380.1 M | Current Value 400.7 M | Quarterly Volatility 200.9 M |
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 64.1 M, Interest Expense of 9.2 M or Selling General Administrative of 26.3 M, as well as many indicators such as Price To Sales Ratio of 1.59, Dividend Yield of 0.31 or PTB Ratio of 1.11. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
Knight | Total Current Assets |
Evaluating Knight Therapeutics's Total Current Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Knight Therapeutics's fundamental strength.
Latest Knight Therapeutics' Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Knight Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Knight Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Knight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Knight Total Current Assets Regression Statistics
| Arithmetic Mean | 395,102,719 | |
| Geometric Mean | 4,423,458 | |
| Coefficient Of Variation | 69.16 | |
| Mean Deviation | 204,253,332 | |
| Median | 396,813,000 | |
| Standard Deviation | 273,258,466 | |
| Sample Variance | 74670.2T | |
| Range | 799.8M | |
| R-Value | 0.39 | |
| Mean Square Error | 67600.3T | |
| R-Squared | 0.15 | |
| Significance | 0.12 | |
| Slope | 21,046,107 | |
| Total Sum of Squares | 1194723T |
Knight Total Current Assets History
About Knight Therapeutics Financial Statements
Knight Therapeutics investors utilize fundamental indicators, such as Total Current Assets, to predict how Knight Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Assets | 357.1 M | 397.5 M |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.